Pharmabiz3d
DFE Pharma expands its C2F Center of Excellence in Hyderabad to advance the development of critical respiratory treatments
DFE Pharma, a global leader in pharmaceutical and biopharmaceutical excipient solutions, has expanded the capabilities of its Closer to the Formulator (C2F) Center of Excellence located in Genome ...
Pharmabiz3d
Illumina launches pilot proteomics programme with UK Biobank and biopharma collaborators to analyze 50,000 samples
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced a pilot proteomics programme to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, ...
Pharmabiz3d
India initiates anti-dumping probe on Resorcinol imports from China and Japan
The Directorate General of Trade Remedies (DGTR) has issued an updated notification concerning the ongoing anti-dumping investigation into imports of Resorcinol from China PR and Japan. The ...
Pharmabiz3d
PDMA asks govt to create separate category for units below Rs. 10 crore & allow 3 years to implement revised Schedule M
The Punjab Drug Manufacturers Association (PDMA) has sought the Union ministry of health and family welfare to create a separate category for units below Rs. 10 crore turnover outside the erstwhile ...
Pharmabiz3d
China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma
The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...
Pharmabiz4d
Exporters concerned over delay in getting relief under Section 43B(h) of IT Act
India’s pharmaceutical exporters are on edge as they await a decisive response from the government regarding their long pending appeal for relief under the restrictive payment conditions of Section ...
Pharmabiz4d
Harbour BioMed announces license agreement with Windward Bio for HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases
Harbour BioMed, a global biopharmaceutical company, announced that the company and Sichuan Kelun Biotech BioPharmaceutical have entered into a license agreement with Windward Bio AG (Windward Bio) for ...
Pharmabiz3d
Pharmacy Council of India fixes staff to students ratio for B.Pharm as 1:20
The Pharmacy Council of India (PCI) has stipulated that the staff to student ratio for Bachelor of Pharmacy (B.Pharm) courses should not exceed 1:20 in theory classes and practical classes. The ...
Pharmabiz4d
Panel asks govt to provide duty concessions, reduced GST rates for growth of medical devices manufacturing
A Parliamentary panel has sought the ministry of chemicals and fertilisers to facilitate attractive duty concessions and reasonable reduction in the Goods and Services Tax (GST) rates in consultation ...
Pharmabiz4d
BioDuro opens new solid-phase peptide synthesis scale-up facility in China
BioDuro, a leading contract research, development, and manufacturing organization (CRDMO), announced the opening of a fully-automated solid-phase peptide synthesis scale-up laboratory at its Shanghai ...
Pharmabiz4d
Lupin introduces Minzoya in US market
Global pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration (FDA) approved Minzoya (levonorgestrel and ethinyl estradiol tablets, USP and ferrous ...